Alex Chang

Research output

Research output per year 1973 1982 1986 1988 1989 1993 1994 1995 1996 1997 1998 1999 2000 2006 2007 2008 2011 2013 2018 2020 2022

• 123 Article
• 12 Review article
• 6 Letter
• 5 Editorial
• 3 More
  • 3 Comment/debate

Research output per year

Research output per year

Search results

• 2022

  Combination of osimertinib and pembrolizumab successfully overcome dual resistances in a patient with advanced adenocarcinoma of the lung, a case report

  Kulendran, L., Chia, P. L., Samol, J. & Chang, A. Y., Mar 2022, In: Current Problems in Cancer: Case Reports. 5, 100132.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • osimertinib 100%
  • pembrolizumab 88%
  • Adenocarcinoma of Lung 67%
  • ErbB Receptors 59%
  • Exons 52%
• 2020

  Clinical outcome event adjudication in a 10-year prospective study of nucleos(T)ide analogue therapy for chronic hepatitis b

  Lim, J. K., Chang, A. Y., Zaman, A., Martin, P., Fernandez-Rodriguez, C. M., Korkmaz, M., Rossi, S., Ford, J. M., Noonan, T., Cooney, E., Navarro, V. & Colombato, L., 2020, In: Journal of Clinical and Translational Hepatology. 8, 4, p. 377-384 8 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Chronic Hepatitis 100%
  • Hepatitis B virus 90%
  • entecavir 88%
  • Chronic Hepatitis B 66%
  • Data Accuracy 65%

• Lung cancer and family-centered concerns

  Feliciano, J., Chang, A., Venkatraman, D., Brooks, S., Zagaja, C., Ettinger, D., Hann, C., Naidoo, J., Voong, R., Hales, R., Turner, M., Peterson, V. & Bodurtha, J., Feb 1 2020, In: Supportive Care in Cancer. 28, 2, p. 497-505 9 p.

  Research output: Contribution to journal › Article › peer-review

  • Lung Neoplasms 100%
  • Focus Groups 24%
  • Caregivers 21%
  • Grounded Theory 14%
  • Family Health 14%

• Lung cancer management during the COVID-19 pandemic: experience of a medical oncology unit at a tertiary hospital in Singapore

  Vong, E. K. Y., Chia, P. L. & Chang, A. Y., 2020, In: Journal of Cancer Metastasis and Treatment. 6, 3833.

  Research output: Contribution to journal › Review article › peer-review

  Open Access

  • Coronavirus 100%
  • Medical Oncology 94%
  • Singapore 91%
  • Pandemics 84%
  • Tertiary Care Centers 69%

• One-pot synthesis of theranostic nanocapsules with lanthanide doped nanoparticles

  Wang, M., Zhang, Y., Ng, M., Skripka, A., Cheng, T., Li, X., Bhakoo, K. K., Chang, A. Y., Rosei, F. & Vetrone, F., Jul 14 2020, In: Chemical Science. 11, 26, p. 6653-6661 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Nanocapsule 100%
  • One Pot Reaction 73%
  • Lanthanoid Atom 61%
  • Zinc Phthalocyanine 54%
  • Nanoparticle 41%
  1 Scopus citations
• 2019

  Development of a Liposomal Formulation of Acetyltanshinone IIA for Breast Cancer Therapy

  Wang, Q., Luo, M., Wei, N., Chang, A. & Luo, K. Q., Sep 3 2019, In: Molecular Pharmaceutics. 16, 9, p. 3873-3886 14 p.

  Research output: Contribution to journal › Article › peer-review

  • acetyltanshinone IIA 100%
  • Bioavailability 41%
  • Breast Neoplasms 26%
  • Tamoxifen 19%
  • Estrogen 15%

• Morphology Control of Lanthanide Doped NaGdF₄ Nanocrystals via One-Step Thermolysis

  Wang, M., Zhang, Y., Yao, Q., Ng, M., Lin, M., Li, X., Bhakoo, K. K., Chang, A. Y., Rosei, F. & Vetrone, F., Jul 23 2019, In: Chemistry of Materials. 31, 14, p. 5160-5171 12 p.

  Research output: Contribution to journal › Article › peer-review

  • Thermolysis 100%
  • Nanocrystals 91%
  • Rare earth elements 85%
  • Nanorods 72%
  • Nanocrystal 49%
  14 Scopus citations

• Real world experience on treatment, outcome and toxicity of crizotinib in patients with anaplastic lymphoma kinase positive advanced non-small cell lung cancer

  Del Valle, M. F. F. & Chang, A. Y. C., Sep 1 2019, In: Journal of Thoracic Disease. 11, 9, p. 3864-3873 10 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Crizotinib 100%
  • Anaplastic Lymphoma Kinase 92%
  • Non-Small Cell Lung Carcinoma 61%
  • Cardiotoxicity 14%
  • Progression-Free Survival 11%
• 2018

  Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: An international, multicenter study of the mayo clinic phase 2 consortium (NCI-9742)

  Ma, B. B. Y., Lim, W. T., Goh, B. C., Hui, E. P., Lo, K. W., Pettinger, A., Foster, N. R., Riess, J. W., Agulnik, M., Chang, A. Y. C., Chopra, A., Kish, J. A., Chung, C. H., Adkins, D. R., Cullen, K. J., Gitlitz, B. J., Lim, D. W., To, K. F., Chan, K. C. A., Lo, Y. M. D., & 5 othersKing, A. D., Erlichman, C., Yin, J., Costello, B. A. & Chan, A. T. C., 2018, In: Journal of Clinical Oncology. 36, 14, p. 1412-1418 7 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Nivolumab 100%
  • Nasopharyngeal Carcinoma 83%
  • Multicenter Studies 63%
  • Survival Rate 44%
  • Ligands 41%
  120 Scopus citations

• Integrated genomic analyses in PDX model reveal a cyclin-dependent kinase inhibitor Palbociclib as a novel candidate drug for nasopharyngeal carcinoma

  Hsu, C. L., Lui, K. W., Chi, L. M., Kuo, Y. C., Chao, Y. K., Yeh, C. N., Lee, L. Y., Huang, Y., Lin, T. L., Huang, M. Y., Lai, Y. R., Yeh, Y. M., Fan, H. C., Lin, A. C., Lu, Y. J., Hsieh, C. H., Chang, K. P., Tsang, N. M., Wang, H. M., Chang, A. Y., & 2 othersChang, Y. S. & Li, H. P., Sep 20 2018, In: Journal of Experimental and Clinical Cancer Research. 37, 1, 233.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • palbociclib 100%
  • Cyclin-Dependent Kinases 73%
  • Nasopharyngeal Carcinoma 71%
  • Heterografts 56%
  • Pharmaceutical Preparations 25%
  14 Scopus citations

• Molecular mechanism of action and potential biomarkers of growth inhibition of synergistic combination of afatinib and dasatinib against gefitinib-resistant non-small cell lung cancer cells

  Wang, M. & Chang, A. Y. C., 2018, In: Oncotarget. 9, 23, p. 16533-16546 14 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Afatinib 100%
  • Dasatinib 90%
  • Gefitinib 82%
  • Action Potentials 59%
  • Non-Small Cell Lung Carcinoma 58%
  7 Scopus citations

• Non-invasive detection of actionable mutations in advanced non-small-cell lung cancer using targeted sequencing of circulating tumor DNA

  Sim, W. C., Loh, C. H., Toh, G. L. X., Lim, C. W., Chopra, A., Chang, A. Y. C. & Goh, L. L., Oct 2018, In: Lung Cancer. 124, p. 154-159 6 p.

  Research output: Contribution to journal › Article › peer-review

  • Circulating Tumor DNA 100%
  • Non-Small Cell Lung Carcinoma 62%
  • High-Throughput Nucleotide Sequencing 39%
  • Mutation 38%
  • Genes 16%
  12 Scopus citations
• 2017

  Aristolochic acids and their derivatives are widely implicated in liver cancers in Taiwan and throughout Asia

  Ng, A. W. T., Poon, S. L., Huang, M. N., Lim, J. Q., Boot, A., Yu, W., Suzuki, Y., Thangaraju, S., Ng, C. C. Y., Tan, P., Pang, S. T., Huang, H. Y., Yu, M. C., Lee, P. H., Hsieh, S. Y., Chang, A. Y., Teh, B. T. & Rozen, S. G., Oct 18 2017, In: Science translational medicine. 9, 412, eaan6446.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Aristolochic Acids 100%
  • Liver Neoplasms 52%
  • Taiwan 52%
  • Hepatocellular Carcinoma 42%
  • Aristolochia 11%
  136 Scopus citations

• Enhancement of the bioavailability of a novel anticancer compound (acetyltanshinone IIA) by encapsulation within mPEG-PLGA nanoparticles: A study of formulation optimization, toxicity, and pharmacokinetics

  Wang, Q., Wei, N., Liu, X., Chang, A. & Luo, K. Q., 2017, In: Oncotarget. 8, 7, p. 12013-12030 18 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • acetyltanshinone IIA 100%
  • methoxypolyethyleneglycol-poly(lactic-co-glycolic acid) 81%
  • Biological Availability 38%
  • Nanoparticles 37%
  • Pharmacokinetics 31%
  9 Scopus citations
• 2016

  Phase II study of neo-adjuvant chemotherapy for locally advanced gastric cancer

  Chang, A. Y. C., Foo, K. F., Koo, W. H., Ong, S., So, J., Tan, D. & Lim, K. H., Dec 31 2016, In: BMJ Open Gastroenterology. 3, 1, e000095.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Adjuvant Chemotherapy 100%
  • Stomach Neoplasms 85%
  • Capecitabine 41%
  • Docetaxel 36%
  • Neutropenia 21%
  2 Scopus citations
• 2015

  Brain metastases from breast cancer and response to treatment with eribulin: A case series

  Chang, A. Y. & Ying, X. X., Mar 12 2015, In: Breast Cancer: Basic and Clinical Research. 9, p. 19-24 6 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • eribulin 100%
  • Capecitabine 54%
  • Breast Neoplasms 38%
  • Neoplasm Metastasis 37%
  • Brain 29%
  13 Scopus citations

• Singapore cancer network (SCAN) guidelines for adjuvant chemotherapy in resected non-small cell lung cancer

  The Singapore Cancer Network (SCAN) Lung Cancer Workgroup, Oct 2015, In: Annals of the Academy of Medicine Singapore. 44, 10, p. 440-448 9 p.

  Research output: Contribution to journal › Article › peer-review

  • Singapore 100%
  • Adjuvant Chemotherapy 87%
  • Non-Small Cell Lung Carcinoma 77%
  • Guidelines 55%
  • Practice Guidelines 32%

• Singapore cancer network (SCAN) guidelines for the use of systemic therapy in advanced non-small cell lung cancer

  The Singapore Cancer Network (SCAN) Lung Cancer Workgroup, Oct 2015, In: Annals of the Academy of Medicine Singapore. 44, 10, p. 449-462 14 p.

  Research output: Contribution to journal › Article › peer-review

  • Singapore 100%
  • Non-Small Cell Lung Carcinoma 77%
  • Guidelines 55%
  • Practice Guidelines 40%
  • Lung Neoplasms 34%
  2 Scopus citations
• 2014

  Silica-F127 nanohybrid-encapsulated manganese oxide nanoparticles for optimized T₁ magnetic resonance relaxivity

  Wei Hsu, B. Y., Wang, M., Zhang, Y., Vijayaragavan, V., Wong, S. Y., Yuang-Chi Chang, A., Bhakoo, K. K., Li, X. & Wang, J., Jan 7 2014, In: Nanoscale. 6, 1, p. 293-299 7 p.

  Research output: Contribution to journal › Article › peer-review

  • Manganese oxide 100%
  • Magnetic Resonance 65%
  • Magnetic resonance 65%
  • Silica 64%
  • Nanoparticles 62%
  28 Scopus citations
• 2013

  Can we improve quality of life of patients on dialysis?

  Jaar, B. G., Chang, A. & Plantinga, L., Jan 7 2013, In: Clinical Journal of the American Society of Nephrology. 8, 1, p. 1-4 4 p.

  Research output: Contribution to journal › Editorial › peer-review

  Open Access
  30 Scopus citations

• In-vitro growth inhibition of chemotherapy and molecular targeted agents in hepatocellular carcinoma

  Chang, A. Y. & Wang, M., Mar 1 2013, In: Anti-cancer drugs. 24, 3, p. 251-259 9 p.

  Research output: Contribution to journal › Article › peer-review

  • BMS 536924 100%
  • Dasatinib 65%
  • ixabepilone 64%
  • Hepatocellular Carcinoma 61%
  • brivanib 54%
  19 Scopus citations

• Molecular mechanisms of action and potential biomarkers of growth inhibition of dasatinib (BMS-354825) on hepatocellular carcinoma cells

  Chang, A. Y. & Wang, M., May 30 2013, In: BMC cancer. 13, 267.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Dasatinib 100%
  • Action Potentials 65%
  • src-Family Kinases 61%
  • Hepatocellular Carcinoma 58%
  • Biomarkers 47%
  29 Scopus citations

• PEOlated micelle/silica as dual-layer protection of quantum dots for stable and targeted bioimaging

  Zhang, Y., Wang, M., Zheng, Y. G., Tan, H., Hsu, B. Y. W., Yang, Z. C., Wong, S. Y., Chang, A. Y. C., Choolani, M., Li, X. & Wang, J., Aug 13 2013, In: Chemistry of Materials. 25, 15, p. 2976-2985 10 p.

  Research output: Contribution to journal › Article › peer-review

  • Polyethylene oxides 100%
  • Micelles 98%
  • Silica 67%
  • Quantum Dot 58%
  • Micelle 51%
  52 Scopus citations

• Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial)

  Ramalingam, S., Crawford, J., Chang, A., Manegold, C., Perez-Soler, R., Douillard, J. Y., Thatcher, N., Barlési, F., Owonikoko, T., Wang, Y., Pultar, P., Zhu, J., Malik, R., Giaccone, G., Della-Fiorentina, S., Begbie, S., Jennens, R., Dass, J., Pittman, K., Ivanova, N., & 168 othersKoynova, T., Petrov, P., Tomova, A., Tzekova, V., Couture, F., Hirsh, V., Burkes, R., Sangha, R., Ambrus, M., Janaskova, T., Musil, J., Novotny, J., Zatloukal, P., Jakesova, J., Klenha, K., Roubec, J., Vanasek, J., Fayette, J., Bennouna-Louridi, J., Chouaid, C., Mazières, J., Vallerand, H., Robinet, G., Souquet, P. J., Spaeth, D., Schott, R., Lena, H., Martinet, Y., El Kouri, C., Baize, N., Scherpereel, A., Molinier, O., Fuchs, F., Josten, K. M., Marschner, N., Schneller, F., Overbeck, T., Thomas, M., von Pawel, J., Reck, M., Schuette, W., Hagen, V., Schneider, C. P., Georgoulias, V., Varthalitis, I., Zarogoulidis, K., Syrigos, K., Papandreou, C., Bocskei, C., Csanky, E., Juhasz, E., Losonczy, G., Mark, Z., Molnar, I., Papai-Szekely, Z., Tehenes, S., Vinkler, I., Almel, S., Bakshi, A., Bondarde, S., Maru, A., Pathak, A., Pedapenki, R. M., Prasad, K., V S S Prasad, S., Kilara, N., Gorijavolu, D., Deshmukh, C. D., John, S., Sharma, L. M., Amoroso, D., Bajetta, E., Bidoli, P., Bonetti, A., De Marinis, F., Maio, M., Passalacqua, R., Cascinu, S., Bearz, A., Bitina, M., Brize, A., Purkalne, G., Skrodele, M., Baba, A. A., Ratnavelu, K., Saw, M. H., Samson-Fernando, M. C., Ladrera, G. E., Jassem, J., Koralewski, P., Serwatowski, P., Krzakowski, M., Cebotaru, C., Filip, D., Ganea-Motan, D. E., Ianuli, C. H., Manolescu, I. G., Udrea, A., Burdaeva, O., Byakhov, M., Filippov, A., Lazarev, S., Mosin, I., Orlov, S., Udovitsa, D., Khorinko, A., Protsenko, S., Lim, H. L., Tan, Y. O., Tan, E. H., Bastus Piulats, R., Garcia-Foncillas, J., Valdivia, J., de Castro, J., Domine Gomez, M., Kim, S. W., Lee, J. S., Kim, H. K., Lee, J. S., Shin, S. W., Kim, D. W., Kim, Y. C., Park, K. C., Chang, C. S., Chang, G. C., Goan, Y. G., Su, W. C., Tsai, C. M., Kuo, H. P., Benekli, M., Demir, G., Gokmen, E., Sevinc, A., Haigentz, M., Agarwal, M., Pandit, S., Araujo, R., Vrindavanam, N., Bonomi, P., Berg, A., Wade, J., Bloom, R., Amin, B., Camidge, R., Hill, D., Rarick, M., Flynn, P., Klein, L., Lo Russo, K., Neubauer, M., Richards, P., Ruxer, R., Savin, M., Weckstein, D., Rosenberg, R., Whittaker, T., Richards, D., Berry, W., Ottensmeier, C., Dangoor, A., Steele, N., Summers, Y., Rankin, E., Rowley, K., Giridharan, S., Kristeleit, H., Humber, C. & Taylor, P., Nov 2013, In: Annals of Oncology. 24, 11, p. 2875-2880 6 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • talactoferrin alfa 100%
  • Non-Small Cell Lung Carcinoma 43%
  • Placebos 33%
  • Survival Rate 18%
  • Progression-Free Survival 14%
  37 Scopus citations
• 2012

  Favorable response to neoadjuvant chemotherapy and radiation in a patient with prostatic stromal sarcoma

  Reese, A. C., Ball, M. W., Efron, J. E., Chang, A., Meyer, C. & Bivalacqua, T. J., Nov 20 2012, In: Journal of Clinical Oncology. 30, 33, p. e353-e355

  Research output: Contribution to journal › Article › peer-review

  Open Access
  6 Scopus citations

• Silica-shell cross-linked micelles encapsulating fluorescent conjugated polymers for targeted cellular imaging

  Tan, H., Zhang, Y., Wang, M., Zhang, Z., Zhang, X., Yong, A. M., Wong, S. Y., Chang, A. Y. C., Chen, Z. K., Li, X., Choolani, M. & Wang, J., Jan 2012, In: Biomaterials. 33, 1, p. 237-246 10 p.

  Research output: Contribution to journal › Article › peer-review

  • Conjugated polymers 100%
  • Micelles 84%
  • Silicon Dioxide 64%
  • Silica 57%
  • Conjugated Polymer 56%
  47 Scopus citations
• 2011

  Bevacizumab in combination with oxaliplatin and doxorubicin or liposomal doxorubicin for hepatocellular cancer: A case series

  Ku, G. Y., De Lima Lopes, G. & Chang, A. Y., Jun 2011, In: Asia-Pacific Journal of Clinical Oncology. 7, 2, p. 174-179 6 p.

  Research output: Contribution to journal › Article › peer-review

  • liposomal doxorubicin 100%
  • Oxaliplatin 84%
  • Bevacizumab 79%
  • Liver Neoplasms 70%
  • Doxorubicin 65%
  2 Scopus citations

• Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC

  Chang, A., Jan 2011, In: Lung Cancer. 71, 1, p. 3-10 8 p.

  Research output: Contribution to journal › Review article › peer-review

  • Non-Small Cell Lung Carcinoma 100%
  • Drug Therapy 65%
  • ABT751 33%
  • amminedichloro(2-methylpyridine)platinum(II) 31%
  • Epothilones 26%
  299 Scopus citations

• Final results of a prematurely discontinued Phase 1/2 study of eniluracil with escalating doses of 5-fluorouracil administered orally in patients with advanced hepatocellular carcinoma

  De Lima Lopes, G., Dicksey, J. S., Peters, W. P., Palalay, M. & Chang, A. Y., Oct 2011, In: Cancer Chemotherapy and Pharmacology. 68, 4, p. 1067-1073 7 p.

  Research output: Contribution to journal › Article › peer-review

  • eniluracil 100%
  • 5-Fluorouracil 63%
  • Fluorouracil 50%
  • Hepatocellular Carcinoma 42%
  • Dose 40%
  5 Scopus citations

• Intrinsically fluorescent carbon dots with tunable emission derived from hydrothermal treatment of glucose in the presence of monopotassium phosphate

  Yang, Z. C., Wang, M., Yong, A. M., Wong, S. Y., Zhang, X. H., Tan, H., Chang, A. Y., Li, X. & Wang, J., Nov 14 2011, In: Chemical Communications. 47, 42, p. 11615-11617 3 p.

  Research output: Contribution to journal › Article › peer-review

  • Phosphates 100%
  • Glucose 98%
  • Carbon 65%
  • Phosphate 57%
  • Fluorescence 50%
  393 Scopus citations

• Pemetrexed in the treatment of thoracic malignancies: A single centre experience in Singapore

  Lopes, G., Chopra, A., Kukutschka, J., Portillo, P., Bharwani, L. & Chang, A., Mar 2011, In: Singapore Medical Journal. 52, 3, p. 190-194 5 p.

  Research output: Contribution to journal › Review article › peer-review

  • Pemetrexed 100%
  • Singapore 87%
  • Thorax 52%
  • Non-Small Cell Lung Carcinoma 29%
  • Mesothelioma 25%
  1 Scopus citations
• 2009

  Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer

  Olive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M. A., Caldwell, M. E., Allard, D., Frese, K. K., DeNicola, G., Feig, C., Combs, C., Winter, S. P., Ireland-Zecchini, H., Reichelt, S., Howat, W. J., Chang, A., Dhara, M., & 17 othersWang, L., Rückert, F., Grützmann, R., Pilarsky, C., Izeradjene, K., Hingorani, S. R., Huang, P., Davies, S. E., Plunkett, W., Egorin, M., Hruban, R. H., Whitebread, N., McGovern, K., Adams, J., Iacobuzio-Donahue, C., Griffiths, J. & Tuveson, D. A., Jun 12 2009, In: Science. 324, 5933, p. 1457-1461 5 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Hedgehogs 100%
  • Pancreatic Neoplasms 71%
  • gemcitabine 63%
  • Drug Therapy 44%
  • Adenocarcinoma 44%
  2123 Scopus citations

• Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC)

  Lim, E. H., Zhang, S. L., Li, J. L., Yap, W. S., Howe, T. C., Tan, B. P., Lee, Y. S., Wong, D., Khoo, K. L., Seto, K. Y., Tan, L., Agasthian, T., Koong, H. N., Tam, J., Tan, C., Caleb, M., Chang, A., Ng, A. & Tan, P., Jan 2009, In: Journal of Thoracic Oncology. 4, 1, p. 12-21 10 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • ErbB Receptors 100%
  • Non-Small Cell Lung Carcinoma 93%
  • Genome 71%
  • Biopsy 63%
  • Mutation 58%
  56 Scopus citations
• 2008

  Breast cancer in the Asia-Pacific region

  Chang, A. Y. C., 2008, In: Asia-Pacific Journal of Clinical Oncology. 4, SUPPL. 3, p. S3-S4

  Research output: Contribution to journal › Editorial › peer-review

• Clinical experience with gefitinib in Indian patients

  Parikh, P., Chang, A. Y. C., Nag, S., Digumarti, R., Bhattacharyya, G. S., Doval, D. C., Babu, G., Chacko, R. T., Advani, S., Ranade, A., Aggarwal, S., Jagannathan, R., Hargreaves, L. & Thatcher, N., Apr 2008, In: Journal of Thoracic Oncology. 3, 4, p. 380-385 6 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Gefitinib 100%
  • Survival 24%
  • India 23%
  • Lung 14%
  • Placebos 12%
  20 Scopus citations

• Detection and comparison of epidermal growth factor receptor mutations in cells and fluid of malignant pleural effusion in non-small cell lung cancer

  Zhang, X., Zhao, Y., Wang, M., Yap, W. S. & Chang, A. Y. C., May 2008, In: Lung Cancer. 60, 2, p. 175-182 8 p.

  Research output: Contribution to journal › Article › peer-review

  • Malignant Pleural Effusion 100%
  • ErbB Receptors 69%
  • Non-Small Cell Lung Carcinoma 65%
  • Mutation 40%
  • Polymerase Chain Reaction 14%
  65 Scopus citations

• Dyspnea and hemoptysis in a 53-year-old woman with a history of breast cancer

  Koethe, J. R. & Chang, A. Y., May 2008, In: CHEST. 133, 5, p. 1248-1251 4 p.

  Research output: Contribution to journal › Article › peer-review
  1 Scopus citations

• Male breast cancers: Finding clues from controversies and insufficient data

  Chang, A., Mar 2008, In: Asia-Pacific Journal of Clinical Oncology. 4, 1, p. 1 1 p.

  Research output: Contribution to journal › Editorial › peer-review

  Open Access

• Molecular predictors of EGFR-TKI sensitivity in advanced non-small cell lung cancer

  Zhang, X. & Chang, A., Jul 11 2008, In: International journal of medical sciences. 5, 4, p. 209-217 9 p.

  Research output: Contribution to journal › Review article › peer-review

  Open Access

  • ErbB Receptors 100%
  • Protein-Tyrosine Kinases 95%
  • Non-Small Cell Lung Carcinoma 93%
  • Mutation 41%
  • Gene Dosage 35%
  69 Scopus citations

• Optimizing the management of advanced breast cancer in the Asia-Pacific region: Role of clinical trials and treatment guidelines

  Chen, S. C. & Chang, A. Y. C., 2008, In: Asia-Pacific Journal of Clinical Oncology. 4, SUPPL. 3, p. S24-S29

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Clinical Trials 100%
  • Guidelines 98%
  • Breast Neoplasms 97%
  • Therapeutics 25%
  • Appointments and Schedules 25%

• The role of gefitinib in the management of Asian patients with non-small cell lung cancer

  Chang, A. Y., Mar 2008, In: Expert Opinion on Investigational Drugs. 17, 3, p. 401-411 11 p.

  Research output: Contribution to journal › Review article › peer-review

  • Gefitinib 100%
  • Non-Small Cell Lung Carcinoma 71%
  • ErbB Receptors 32%
  • Lung Neoplasms 27%
  • Gene Dosage 13%
  10 Scopus citations
• 2007

  An alternative approach to determining therapeutic choices in advanced non-small cell lung carcinoma (NSCLC): Maximizing the diagnostic procedure and the use of low-volume lung biopsies

  Lim, E. H., Zhang, S. L., Yu, K., Nga, M. E., Ahmed, D. A., Agasthian, T., Wong, P. S., Chua, G. C., Wong, D., Tan, L., Seto, K. Y., Yap, W. S., Low, S. P., Khoo, K. L., Chang, A., Ng, A. & Tan, P., May 2007, In: Journal of Thoracic Oncology. 2, 5, p. 387-396 10 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Non-Small Cell Lung Carcinoma 100%
  • ErbB Receptors 79%
  • Exons 69%
  • Biopsy 67%
  • Lung 59%
  16 Scopus citations

• Comparison of clinical with pathological nodal staging from systematic mediastinal lymph node dissection in early resectable non-small cell lung cancer

  Chong, C. F., Khoo, K. L., Lim, T. K., Chang, A. Y., Lim, H. L., Lee, C. N. & Wong, P. S., Jul 2007, In: Singapore Medical Journal. 48, 7, p. 620-624 5 p.

  Research output: Contribution to journal › Article › peer-review

  • Lymph Node Excision 100%
  • Non-Small Cell Lung Carcinoma 91%
  • Lymph Nodes 18%
  • Tomography 17%
  • Carcinoma 16%
  3 Scopus citations

• Phase II trial of 5-fluorouracil/leucovorin/gemcitabine/cisplatin as second-line treatment in patients with metastatic or recurrent colorectal carcinoma: A cancer therapeutics research group study

  Chang, A. Y., Lopes, G., Koo, W. H., Lim, R., Foo, K. F. & Wong, J., Sep 2007, In: Clinical colorectal cancer. 6, 9, p. 646-651 6 p.

  Research output: Contribution to journal › Article › peer-review

  • Therapeutic Human Experimentation 100%
  • Leucovorin 88%
  • gemcitabine 82%
  • Fluorouracil 70%
  • Cisplatin 66%
  5 Scopus citations

• Somatic mutations of the epidermal growth factor receptor and non-small-cell lung cancer

  Zhang, X. & Chang, A., Mar 2007, In: Journal of medical genetics. 44, 3, p. 166-172 7 p.

  Research output: Contribution to journal › Review article › peer-review

  • ErbB Receptors 100%
  • Erlotinib Hydrochloride 99%
  • Gefitinib 98%
  • Non-Small Cell Lung Carcinoma 93%
  • Mutation 58%
  41 Scopus citations

• Targeted therapy in colorectal cancer: Inequality of care between those who have and those who have not

  Chang, A. Y., Mar 2007, In: Asia-Pacific Journal of Clinical Oncology. 3, 1, p. 1 1 p.

  Research output: Contribution to journal › Editorial › peer-review
  1 Scopus citations
• 2006

  Differential reactions of microglia to brain metastasis of lung cancer

  He, B. P., Wang, J. J., Zhang, X., Wu, Y., Wang, M., Bay, B. H. & Chang, A. Y. C., Jul 2006, In: Molecular Medicine. 12, 7-8, p. 161-170 10 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Microglia 100%
  • Lung Neoplasms 77%
  • Neoplasm Metastasis 60%
  • Brain 48%
  • Neoplasms 19%
  59 Scopus citations

• Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: Subset analysis from the ISEL study

  Chang, A., Parikh, P., Thongprasert, S., Tan, E. H., Perng, R. P., Ganzon, D., Yang, C. H., Tsao, C. J., Watkins, C., Botwood, N. & Thatcher, N., Oct 1 2006, In: Journal of Thoracic Oncology. 1, 8, p. 847-855 9 p.

  Research output: Contribution to journal › Article › peer-review

  • Gefitinib 100%
  • Survival Analysis 77%
  • Non-Small Cell Lung Carcinoma 71%
  • Lung Neoplasms 63%
  • Placebos 38%
  172 Scopus citations

• Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer

  Hirsch, F. R., Varella-Garcia, M., Bunn, P. A., Franklin, W. A., Dziadziuszko, R., Thatcher, N., Chang, A., Parikh, P., Pereira, J. R., Ciuleanu, T., Von Pawel, J., Watkins, C., Flannery, A., Ellison, G., Donald, E., Knight, L., Parums, D., Botwood, N. & Holloway, B., Nov 1 2006, In: Journal of Clinical Oncology. 24, 31, p. 5034-5042 9 p.

  Research output: Contribution to journal › Article › peer-review

  • Gefitinib 100%
  • Non-Small Cell Lung Carcinoma 71%
  • Placebos 55%
  • ErbB Receptors 47%
  • Gene Dosage 35%
  661 Scopus citations

• Pharmacokinetics of intravenously administered stealth liposomal doxorubicin modulated with verapamil in rats

  Wang, J. C., Liu, X. Y., Lu, W. L., Chang, A., Zhang, Q., Goh, B. C. & Lee, H. S., Jan 2006, In: European Journal of Pharmaceutics and Biopharmaceutics. 62, 1, p. 44-51 8 p.

  Research output: Contribution to journal › Article › peer-review

  • liposomal doxorubicin 100%
  • Verapamil 93%
  • Doxorubicin 74%
  • Pharmacokinetics 53%
  • ATP Binding Cassette Transporter, Subfamily B, Member 1 13%
  34 Scopus citations